Do you want to read an article? Please log in or register.
Osimertinib-induced aplastic anemia after curative surgery for EGFR-mutant lung adenocarcinoma
Lung Cancer
Related content
Lung Cancer
Aumolertinib Versus Osimertinib as First-Line Treatment for EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Multicenter Study
Int J Cancer
Wang J, Qi P, Li J, Wang N, Fu C, Liu L, Li S, Li X, Hou X, Qiao H
doi: 10.1002/ijc.70617
Lung Cancer
Survival outcomes of patients with uncommon EGFR mutations in surgically resected lung adenocarcinoma: A multi-institutional real-world database study (CReGYT-01 EGFR study)
Lung Cancer
Hayasaka K, Shimokawa M, Haratake N, Notsuda H, Katsumata S, Hamada A, Nomura K, Fujino K, Yoshikawa M, Suzawa K, Shien K, Suda K, Ohara S, Fukuda S, Kinoshita I, Takamori S, Muto S, Takanashi Y, Mizuno K, Hayakawa T, Sekihara K, Toda M, Matsuo S, Takegahara K, Hashimoto M, Nakahashi K, Endo M, Ozawa H, Fujikawa R, Tomioka Y, Namba K, Matsubara T, Suzuki J, Watanabe H, Takada K, Hoshino H, Kaiho T, Toyoda T, Shiono S, Soh J, Ohde Y, Okada Y
doi: 10.1016/j.lungcan.2026.108908
Further Publications
A case of EGFR-positive lung adenocarcinoma that once transformed into small cell carcinoma but worsened into adenocarcinoma again
Respir Med Case Rep
Tanaka S, Yokota K, Yoshimura N, Tobita S, Yaga M, Ueno K
doi: 10.1016/j.rmcr.2025.102271
RECOMMENDED
Lung Cancer
Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Wang Y, Zhang L, Zhan J, Wen L, Zhao X, Sun H, Chen X, Zhang Y, Chen G, Zhao Y, Huang Y, Fang W, Zhang L, Sun D, Yang Y
doi: 10.1016/j.lungcan.2026.108914
Lung Cancer
Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer
Clin Lung Cancer
Sun F, Nagpal S, Singhal S, Neal JW, Wakelee HA, Myall NJ, Bolan P, Riess JW, Gandara DR, Das MS
doi: 10.1016/j.cllc.2025.08.002
RECOMMENDED
Lung Cancer
Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Barsouk A, Heidlauf A, Goel K, Rushkin L, Anran Huang A, Elghawy O, Yu C, Wang L, Yang D, Kurian M, Reed-Guy L, Sun L, Singh A, Aggarwal C, Cohen RB, Langer C, Marmarelis ME
doi: 10.1016/j.lungcan.2026.108936
Lung Cancer
Impact of Genomic Subtype on Intracranial Outcomes in Treatment-naive EGFR mutant NSCLC with Osimertinib (IGnITE)
J Thorac Oncol
Miao E, Wo E, Boe L, Lee J, Walch H, Yu H, Parker M, Imber B, Chiang J, Hui C, Myall N, Pollom E, Ni L, Braunstein S, Hadley C, Matsui J, Palmer J, Khandekar M, Marciscano A, Shih H, Lee A, Chen LN, Shu CA, Wang T, Boor I, Patil T, Camidge DR, Messing I, Lebow E, Akdemir E, Kotecha R, Carey K, Shi W, Khoja L, Sahgal A, Soliman H, Rusthoven CG, George Pike LR
doi: 10.1016/j.jtho.2026.104114
Lung Cancer
Dexamethasone enhances cold atmospheric-pressure plasma-induced antitumor effects in lung adenocarcinoma partly through ROS-associated apoptosis and suppression of PI3K/AKT signaling
Sci Rep
Kong L, Sun T, Liu C, Sui S, Song W, Ni G
doi: 10.1038/s41598-026-53040-2
RECOMMENDED
Lung Cancer
Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
Adv Ther
Girard N, Macouillard P, Byng D, Meng J, Coerts F, Hunter S, Struebing A, Xiong Y, Park S, Haq MI, Tymejczyk O, Chouaid C, Audigier-Valette C, Debieuvre D, Quantin X, Bosquet L, Pérol M
doi: 10.1007/s12325-025-03465-4